Detection of human immunodeficiency virus-induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1249-1257

  Roc, Anne C ^a   Ances, Beau M ^c   Chawla, Sanjeev ^b   Korczykowski, Marc ^a   Wolf, Ronald L ^b   Kolson, Dennis L ^b   Detre, John A ^a,b   Poptani, Harish ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CHOLINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LACTIC ACID; LAMIVUDINE; LIPID; LOPINAVIR; N ACETYLASPARTIC ACID; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BRAIN NUCLEUS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MARKER; DRUG PENETRATION; ENCEPHALITIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE ANALYSIS; LENTICULAR NUCLEUS; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTIC ACID; ATROPHY; BIOLOGICAL MARKERS; CHOLINE; CORPUS STRIATUM; CREATINE; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; LACTIC ACID; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS;

EID: 34548604336     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.noc60125     Document Type: Article

References (59)

1. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex, II: neuropathology. Ann Neurol. 1986;19(6):525-535.
2. Rottenberg DA, Moeller JR, Strother SC, et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol. 1987;22(6):700-706.
3. Glass JD, Wesselingh SL, Selnes OA, McArthur JC. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology. 1993;43(11):2230- 2237.
4. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol. 1995;38(4):563-570.
5. Meyerhoff DJ, Weiner MW, Fein G. Deep gray matter structures in HIV infection: a proton MR spectroscopic study. AJNR Am J Neuroradiol. 1996;17(5):973-978.
6. Chrysikopoulos HS, Press GA, Grafe MR, Hesselink JR, Wiley CA. Encephalitis caused by human immunodeficiency virus: CT and MR imaging manifestations with clinical and pathologic correlation. Radiology. 1990;175(1):185-191.
7. Post MJ, Berger JR, Quencer RM. Asymptomatic and neurologically symptomatic HIV-seropositive individuals: prospective evaluation with cranial MR imaging. Radiology. 1991;178(1):131-139.
8. Chang L. In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Rev Neurosci. 1995;6(4):365-378.
9. Jarvik JG, Lenkinski RE, Saykin AJ, Jaans A, Frank I. Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(3):247-253.
10. Chong WK, Sweeney B, Wilkinson ID, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology. 1993;188(1):119-124.
11. McConnell JR, Swindells S, Ong CS, et al. Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retroviruses. 1994;10(8):977-982.
12. Barker PB, Lee RR, McArthur JC. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology. 1995;195(1):58-64.
13. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology. 1996;46(3):783-788.
14. Simone IL, Federico F, Tortorella C, et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry. 1998;64(4):516-523.
15. Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology. 1999;53(4):782-789.
16. Tucker KA, Robertson KR, Lin W, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol. 2004;157(1-2):153-162.
17. Stankoff B, Tourbah A, Suarez S, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology. 2001;56(1):112-115.
18. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther. 2004;9(3):431-440.
19. Tarasów E, Wiercinska-Drapalo A, Jaroszewicz J, et al. Antiretroviral therapy and its influence on the stage of brain damage in patients with HIV: 1H MRS evaluation. Med Sci Monit. 2004;10(suppl 3):101-106.
20. Avison MJ, Nath A, Berger JR. Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci. 2002;25(9):468-473.
21. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol. 2004;55(2):257-267.
22. Sacktor N, Haughey N, Cutler R, et al. Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol. 2004;157(1-2):176-184.
23. Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ. 2005;12(suppl 1):893-904.
24. Sacktor N, Skolasky RL, Ernst T, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging. 2005;21(4):325-333.
25. Meltzer CC, Wells SW, Becher MW, Flanigan KM, Oyler GA, Lee RR. AIDS-related MR hyperintensity of the basal ganglia. AJNR Am J Neuroradiol. 1998;19(1):83-89.
26. Ueda A, Gatanaga H, Kikuchi Y, Hasuo K, Kimura S, Oka S. Bilateral lesions in the basal ganglia of a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37(7):978-979.
27. Ellis RJ, Evans SR, Clifford DB, et al; Neurological AIDS Research Consortium; AIDS Clinical Trials Group Study Teams A5001 and A362. Clinical validation of the NeuroScreen. J Neurovirol. 2005;11(6):503-511.
28. Heaton RK, Velin RA, McCutchan JA, et al; HNRC Group; HIV Neurobehavioral Research Center. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. Psychosom Med. 1994;56(1):8-17.
29. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26(3):307-319.
30. Ances BM, Roc AC, Wang J, et al. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology. 2006;66(6):862-866.
31. Remin M, Somorjai RL, Deslauriers R, Princz EJ, Smith IC. 1H magnetic resonance of human tumours: analysis of the transverse relaxation of the methylene protons using continuous distributions of relaxation times. NMR Biomed. 1989;2(4):142-150.
32. Archibald SL, Masliah E, Fennema-Notestine C, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol. 2004;61(3):369-376.
33. Langford D, Marquie-Beck J, de Almeida S, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol. 2006;12(2):100-107.
34. McCutchan A, Letendre S. Pharmacology of antiretroviral drugs in the central nervous system: pharmacokinetics, antiretroviral resistance, and pharmacodynamics. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, eds. The Neurology of AIDS. Oxford, England: Oxford University Press; 2005:729-734.
35. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage. 2002;17(3):1638-1648.
36. Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology. 1992;42(11):2125-2130.
37. Hestad K, McArthur JH, Dal Pan GJ, et al. Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand. 1993;88(2):112-118.
38. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res Hum Retroviruses. 1997;13(12):1055-1066.
39. Suwanwelaa N, Phanuphak P, Phanthumchinda K, et al. Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magn Reson Imaging. 2000;18(7):859-865.
40. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology. 1999;52(5):995-1003.
41. Wilkinson ID, Lunn S, Miszkiel KA, et al. Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS. J Neurol Neurosurg Psychiatry. 1997;63(4):477-482.
42. Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 1995;345(8941):60-61.
43. Katz-Brull R, Lenkinski RE, Du Pasquier RA, Koralnik IJ. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology. 2004;63(5):897-900.
44. Neppl R, Nguyen CM, Bowen W, et al. In vivo detection of postictal perturbations of cerebral metabolism by use of proton MR spectroscopy: preliminary results in a canine model of prolonged generalized seizures. AJNR Am J Neuroradiol. 2001;22(10):1933-1943.
45. Pavlakis SG, Kingsley PB, Kaplan GP, Stacpoole PW, O'Shea M, Lustbader D. Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol. 1998;55(6):849-852.
46. Richards TL. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol. 1991;157(5):1073-1078.
47. King NJ, Ward MH, Holmes KT. Magnetic resonance studies of murine macrophages: proliferation is not a prerequisite for acquisition of an "activated" high resolution spectrum. FEBS Lett. 1991;287(1-2):97-101.
48. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol. 2004;147(1-2):43-49.
49. Cloak CC, Chang L, Ernst T. Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J Neuroimmunol. 2004;157(1-2):147-152.
50. Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol. 2006;201(1):193-202.
51. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117-3121.
52. McManus CM, Weidenheim K, Woodman SE, et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am J Pathol. 2000;156(4):1441-1453.
53. Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol. 1999;163(5):2953-2959.
54. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf. 2005;4(2):201-218.
55. Zhao J, Ben LH, Wu YL, et al. Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J Exp Med. 1999;190(1):101-111.
56. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000;14(3):237-242.
57. Lin CS, Fertikh D, Davis B, Lauerman WC, Henderson F, Schellinger D. 2D CSI proton MR spectroscopy of human spinal vertebra: feasibility studies. J Magn Reson Imaging. 2000;11(3):287-293.
58. Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med. 2001;45(5):765-769.
59. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage. 2004;23(3):928-935.